Citius Pharmaceuticals Launches LYMPHIR, Stock Surges
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 24 2025
0mins
Should l Buy CTXR?
Source: Benzinga
Citius Pharmaceuticals Inc's stock surged by 10.58% in pre-market trading as it crossed above the 5-day SMA, reflecting positive investor sentiment.
This surge is attributed to the successful launch of LYMPHIR™, a novel cancer immunotherapy for cutaneous T-cell lymphoma, which is expected to generate significant revenue with an initial market potential exceeding $400 million. The launch marks a pivotal moment for Citius, transitioning from pre-revenue to revenue-generating status, and is supported by strategic financing of $36 million to bolster its commercialization efforts.
The implications of this launch are substantial, as it not only enhances Citius's market position but also addresses an unmet need in oncology treatment. The company's proactive engagement with the FDA and plans for international market expansion further indicate a strong growth trajectory.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CTXR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CTXR
About CTXR
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Citius Pharmaceuticals Closes $5 Million Registered Direct Offering
- Funding Size: Citius Pharmaceuticals successfully closed a registered direct offering of 5,076,143 shares at $0.985 per share, generating approximately $5 million in gross proceeds, which will be utilized for the commercial launch of LYMPHIR™ and other development initiatives.
- Private Placement: The company concurrently issued unregistered warrants for the purchase of 5,076,143 shares at an exercise price of $0.86 per share, providing additional financial flexibility to support future R&D and marketing efforts.
- Market Strategy: Citius plans to use the net proceeds from this offering to support the commercialization of LYMPHIR™, including milestone and regulatory payments, indicating strong confidence in the market potential of its new product and aiming to enhance its competitive position in the biopharmaceutical sector.
- Compliance and Transparency: The offering was conducted under SEC regulations, ensuring compliance while providing transparent information channels for investors, thereby enhancing market trust in Citius Pharmaceuticals.
See More
Citius Pharmaceuticals Closes $5 Million Direct Offering
- Funding Size: Citius Pharmaceuticals successfully completed a registered direct offering of 5,076,143 shares of common stock at a price of $0.985 per share, with expected gross proceeds of approximately $5 million, which will support the company's future product development initiatives.
- Private Placement: In conjunction with this offering, the company issued unregistered warrants to purchase 5,076,143 shares of common stock at an exercise price of $0.86 per share, enhancing the company's capital structure and providing flexibility for future financing.
- Use of Proceeds: The company intends to use the net proceeds from this offering to support the commercial launch of LYMPHIR™, including milestone, regulatory, and other payments, demonstrating its commitment to market entry for new products.
- Product Pipeline: Citius Pharmaceuticals' late-stage pipeline includes Mino-Lok® and CITI-002 (Halo-Lido), with Mino-Lok achieving primary and secondary endpoints in its Phase 3 trial in 2023, indicating positive progress in critical product development.
See More
Citius Pharmaceuticals Enters Stock Sale Agreement
- Stock Sale Agreement: Citius Pharmaceuticals has entered into a definitive agreement to sell approximately 5.08 million shares of common stock or pre-funded warrants at $0.985 per share, adhering to Nasdaq market rules, with expected gross proceeds of around $5 million to support the commercial launch of its immunotherapy LYMPHIR and general corporate purposes.
- Warrant Issuance: Concurrently, the company will issue warrants allowing the purchase of up to 5.08 million shares at an exercise price of $0.86 per share, which can be exercised immediately and will expire five years after the related registration statement becomes effective, enhancing potential returns for investors.
- Market Reaction: Citius Pharmaceuticals' shares fell 15% in premarket trading to $0.79, reflecting market concerns regarding the financing, which may impact the company's short-term stock performance.
- Use of Proceeds: The net proceeds from this offering will primarily support the marketing of LYMPHIR, indicating the company's strategic focus in the immunotherapy sector while also providing funding for general corporate operations to enhance overall competitiveness.
See More
Citius Pharmaceuticals Completes $5 Million Stock Offering
- Stock Offering Details: Citius Pharmaceuticals has entered into an agreement to sell 5,076,143 shares of common stock at $0.985 per share, expecting gross proceeds of approximately $5 million, which will be used to support the commercial launch of LYMPHIR™ and other development initiatives.
- Clear Use of Proceeds: The funds raised will facilitate milestone and regulatory payments for LYMPHIR™, enhancing the company's competitive position in the critical care products market while also supporting the development of other product candidates.
- Market Reaction Anticipated: Given that this offering is a registered direct offering under Nasdaq rules, it is expected to attract more investor interest in Citius Pharmaceuticals, thereby increasing its market visibility and shareholder confidence.
- Future Development Plans: Citius Pharmaceuticals intends to leverage this financing to advance the commercialization of LYMPHIR™ and is actively engaging with the FDA to ensure a smooth product launch, further expanding its market share.
See More
Citius Oncology Launches LYMPHIR for Cutaneous T-Cell Lymphoma Treatment
- Market Adoption Surge: Following its U.S. launch, Citius Oncology's LYMPHIR has gained broad acceptance across leading cancer centers, with early commercial indicators suggesting accelerating prescribing activity that is expected to enhance integration into community healthcare settings.
- Clinical Research Advancements: Collaborations with top academic institutions are advancing LYMPHIR's clinical development, particularly a study at the University of Minnesota that shows its potential prior to CAR-T therapy, with positive topline data supporting further investigations.
- Strengthened Commercial Execution: Citius Oncology is enhancing market access and product promotion through field team training and medical education initiatives, which are expected to boost LYMPHIR's market demand, tapping into an initial market potential exceeding $400 million.
- International Expansion Plans: The company has executed distribution agreements across Europe and the Middle East, marking the ongoing international expansion of LYMPHIR and further solidifying its competitive position in the global oncology treatment market.
See More
Citius Oncology Launches LYMPHIR, Advancing Cancer Treatment
- Increased Market Adoption: Since the U.S. launch of LYMPHIR in December 2025, 83% of target institutions have included it in their formularies, indicating strong market acceptance and expected future prescription growth.
- Broad Payer Coverage: Approximately 135 health plans now cover LYMPHIR, representing about 80% of insured lives, with no reported reimbursement denials or prior authorization barriers, providing a solid foundation for market penetration.
- Clinical Research Advancements: Citius Oncology is collaborating with leading academic centers to conduct clinical studies on LYMPHIR, with preliminary results indicating its potential in treating relapsed large B-cell lymphoma, further validating its application in immuno-oncology.
- Ongoing Commercial Execution: The company is expanding its marketing team and enhancing interactions with physicians and community centers through medical education and digital campaigns to support the acceleration of LYMPHIR prescriptions, ensuring it meets the growing market demand.
See More
Citius Pharmaceuticals Closes $5 Million Registered Direct Offering
- Funding Size: Citius Pharmaceuticals successfully closed a registered direct offering of 5,076,143 shares at $0.985 per share, generating approximately $5 million in gross proceeds, which will be utilized for the commercial launch of LYMPHIR™ and other development initiatives.
- Private Placement: The company concurrently issued unregistered warrants for the purchase of 5,076,143 shares at an exercise price of $0.86 per share, providing additional financial flexibility to support future R&D and marketing efforts.
- Market Strategy: Citius plans to use the net proceeds from this offering to support the commercialization of LYMPHIR™, including milestone and regulatory payments, indicating strong confidence in the market potential of its new product and aiming to enhance its competitive position in the biopharmaceutical sector.
- Compliance and Transparency: The offering was conducted under SEC regulations, ensuring compliance while providing transparent information channels for investors, thereby enhancing market trust in Citius Pharmaceuticals.
See More
Citius Pharmaceuticals Closes $5 Million Direct Offering
- Funding Size: Citius Pharmaceuticals successfully completed a registered direct offering of 5,076,143 shares of common stock at a price of $0.985 per share, with expected gross proceeds of approximately $5 million, which will support the company's future product development initiatives.
- Private Placement: In conjunction with this offering, the company issued unregistered warrants to purchase 5,076,143 shares of common stock at an exercise price of $0.86 per share, enhancing the company's capital structure and providing flexibility for future financing.
- Use of Proceeds: The company intends to use the net proceeds from this offering to support the commercial launch of LYMPHIR™, including milestone, regulatory, and other payments, demonstrating its commitment to market entry for new products.
- Product Pipeline: Citius Pharmaceuticals' late-stage pipeline includes Mino-Lok® and CITI-002 (Halo-Lido), with Mino-Lok achieving primary and secondary endpoints in its Phase 3 trial in 2023, indicating positive progress in critical product development.
See More
Citius Pharmaceuticals Enters Stock Sale Agreement
- Stock Sale Agreement: Citius Pharmaceuticals has entered into a definitive agreement to sell approximately 5.08 million shares of common stock or pre-funded warrants at $0.985 per share, adhering to Nasdaq market rules, with expected gross proceeds of around $5 million to support the commercial launch of its immunotherapy LYMPHIR and general corporate purposes.
- Warrant Issuance: Concurrently, the company will issue warrants allowing the purchase of up to 5.08 million shares at an exercise price of $0.86 per share, which can be exercised immediately and will expire five years after the related registration statement becomes effective, enhancing potential returns for investors.
- Market Reaction: Citius Pharmaceuticals' shares fell 15% in premarket trading to $0.79, reflecting market concerns regarding the financing, which may impact the company's short-term stock performance.
- Use of Proceeds: The net proceeds from this offering will primarily support the marketing of LYMPHIR, indicating the company's strategic focus in the immunotherapy sector while also providing funding for general corporate operations to enhance overall competitiveness.
See More
Citius Pharmaceuticals Completes $5 Million Stock Offering
- Stock Offering Details: Citius Pharmaceuticals has entered into an agreement to sell 5,076,143 shares of common stock at $0.985 per share, expecting gross proceeds of approximately $5 million, which will be used to support the commercial launch of LYMPHIR™ and other development initiatives.
- Clear Use of Proceeds: The funds raised will facilitate milestone and regulatory payments for LYMPHIR™, enhancing the company's competitive position in the critical care products market while also supporting the development of other product candidates.
- Market Reaction Anticipated: Given that this offering is a registered direct offering under Nasdaq rules, it is expected to attract more investor interest in Citius Pharmaceuticals, thereby increasing its market visibility and shareholder confidence.
- Future Development Plans: Citius Pharmaceuticals intends to leverage this financing to advance the commercialization of LYMPHIR™ and is actively engaging with the FDA to ensure a smooth product launch, further expanding its market share.
See More
Citius Oncology Launches LYMPHIR for Cutaneous T-Cell Lymphoma Treatment
- Market Adoption Surge: Following its U.S. launch, Citius Oncology's LYMPHIR has gained broad acceptance across leading cancer centers, with early commercial indicators suggesting accelerating prescribing activity that is expected to enhance integration into community healthcare settings.
- Clinical Research Advancements: Collaborations with top academic institutions are advancing LYMPHIR's clinical development, particularly a study at the University of Minnesota that shows its potential prior to CAR-T therapy, with positive topline data supporting further investigations.
- Strengthened Commercial Execution: Citius Oncology is enhancing market access and product promotion through field team training and medical education initiatives, which are expected to boost LYMPHIR's market demand, tapping into an initial market potential exceeding $400 million.
- International Expansion Plans: The company has executed distribution agreements across Europe and the Middle East, marking the ongoing international expansion of LYMPHIR and further solidifying its competitive position in the global oncology treatment market.
See More
Citius Oncology Launches LYMPHIR, Advancing Cancer Treatment
- Increased Market Adoption: Since the U.S. launch of LYMPHIR in December 2025, 83% of target institutions have included it in their formularies, indicating strong market acceptance and expected future prescription growth.
- Broad Payer Coverage: Approximately 135 health plans now cover LYMPHIR, representing about 80% of insured lives, with no reported reimbursement denials or prior authorization barriers, providing a solid foundation for market penetration.
- Clinical Research Advancements: Citius Oncology is collaborating with leading academic centers to conduct clinical studies on LYMPHIR, with preliminary results indicating its potential in treating relapsed large B-cell lymphoma, further validating its application in immuno-oncology.
- Ongoing Commercial Execution: The company is expanding its marketing team and enhancing interactions with physicians and community centers through medical education and digital campaigns to support the acceleration of LYMPHIR prescriptions, ensuring it meets the growing market demand.
See More
